Trials / Unknown
UnknownNCT05183243
GH21 Capsules for Advanced Solid Tumors: A Study on Safety and Early Results
A Multicenter, Open-label Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of GH21 Capsules in Subjects With Advanced Solid Tumors
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 68 (estimated)
- Sponsor
- Suzhou Genhouse Bio Co., Ltd. · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Evaluate the safety and tolerability of GH21 in patients with advanced solid tumors. Estimate the maximum tolerated dose (MTD) in patients with advanced solid tumors.
Conditions
- Advanced Solid Tumor
- Non-Small Cell Lung Cancer
- Pancreatic Cancer
- Colorectal Cancer
- Head and Neck Neoplasm
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GH21 Capsule | GH21 for oral administration at doses of Dose A, Dose B, Dose C, Dose D, Dose E and Dose F. |
Timeline
- Start date
- 2022-02-20
- Primary completion
- 2024-12-31
- Completion
- 2025-02-20
- First posted
- 2022-01-10
- Last updated
- 2024-07-16
Locations
9 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05183243. Inclusion in this directory is not an endorsement.